{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,20]],"date-time":"2026-07-20T14:16:43Z","timestamp":1784557003718,"version":"3.55.0"},"reference-count":48,"publisher":"Bioscientifica","license":[{"start":{"date-parts":[[2018,6,6]],"date-time":"2018-06-06T00:00:00Z","timestamp":1528243200000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/3.0\/deed.en_GB"}],"content-domain":{"domain":["edm.bioscientifica.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2018,6,6]]},"abstract":"Summary<\/jats:title>\n We report a case of a 63-year-old man who developed diabetic ketoacidosis (DKA) associated with canagliflozin, a sodium glucose co-transporter 2 (SGLT-2) inhibitor. He presented acutely unwell with a silent myocardial infarction, diverticulitis and DKA with a minimally raised blood glucose level. Standard therapy for DKA was initiated. Despite this, ketonaemia persisted for a total of 12 days after discontinuation of canagliflozin. Glucosuria lasting for several days despite discontinuation of the medications is a recognised phenomenon. However, this is the longest duration of ketonaemia to be reported. The cause of prolonged SGLT-2 inhibition remains uncertain. Deviation from the normal DKA treatment protocol and use of personalised regimens may be required in order to prevent relapse into ketoacidosis while avoiding hypoglycaemia in those that develop this condition.<\/jats:p>\n \n Learning points:<\/jats:title>\n \n \n Diabetic ketoacidosis (DKA) may develop in the presence of lower-than-expected blood glucose levels in patients treated with a sodium glucose co-transporter 2 (SGLT-2) inhibitor.<\/jats:p>\n <\/jats:list-item>\n \n Certain individuals prescribed with SGLT-2 inhibitors may be more at risk of DKA, for example, those with a low beta cell function reserve, excessive alcohol consumption and a low carbohydrate diet.<\/jats:p>\n <\/jats:list-item>\n \n In order to reduce the risk of SGLT-2 inhibitor-associated DKA, all patients must be carefully selected before prescription of the medication and appropriately educated.<\/jats:p>\n <\/jats:list-item>\n \n Increased serum ketone levels and glucosuria have been reported to persist for several days despite discontinuation of their SGLT-2 inhibitor.<\/jats:p>\n <\/jats:list-item>\n \n Physicians should consider individualised treatment regimens for subjects with prolonged DKA in the presence of SGLT-2 inhibition.<\/jats:p>\n <\/jats:list-item>\n <\/jats:list>\n <\/jats:sec>","DOI":"10.1530\/edm-17-0177","type":"journal-article","created":{"date-parts":[[2018,6,6]],"date-time":"2018-06-06T10:15:45Z","timestamp":1528280145000},"update-policy":"https:\/\/doi.org\/10.1530\/crossmarkpolicy-2","source":"Crossref","is-referenced-by-count":7,"title":["Prolonged diabetic ketoacidosis associated with canagliflozin"],"prefix":"10.1530","volume":"2018","author":[{"given":"Gordon","family":"Sloan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tania","family":"Kakoudaki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nishant","family":"Ranjan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"416","reference":[{"key":"ref391","doi-asserted-by":"crossref","first-page":"e3","DOI":"10.2337\/dc15-1797","article-title":"Euglycemic diabetic ketoacidosis in a patient with type 2 diabetes after treatment with empagliflozin","volume":"39","year":"2016","journal-title":"Diabetes Care"},{"key":"ref131","doi-asserted-by":"publisher","first-page":"201639","DOI":"10.2337\/dc16-0728","article-title":"FarjoPDKiddKMReeceJL case of euglycemic diabetic ketoacidosis following long - term empagliflozin therapy https org","journal-title":"Diabetes Care"},{"key":"ref311","doi-asserted-by":"crossref","first-page":"753","DOI":"10.4158\/EP161292.PS","article-title":"American Association of Clinical Endocrinologists and American College of Endocrinology position statement on the association of SGLT-2 inhibitors and diabetic ketoacidosis","volume":"22","year":"2016","journal-title":"Endocrine Practices"},{"key":"ref201","first-page":"1656182","article-title":"Severe ketoacidosis associated with canagliflozin (invokana): a safety concern","volume":"2016","year":"2016","journal-title":"Case Reports in Critical Care"},{"key":"ref31","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1016\/j.diabres.2017.04.017","article-title":"Effects of SGLT-2 inhibitors on diabetic ketoacidosis: a meta-analysis of randomised controlled trials","volume":"130","year":"2017","journal-title":"Diabetes Research and Clinical Practice"},{"key":"ref161","article-title":"Gonz\u00e1lez Sanchidri\u00e1nSG\u00f3mez ArroyoJRLabrador Diabetic ketoacidosis associated to canagliflozin in type diabetes https org","volume":"19","author":"Martino","journal-title":"Medicina"},{"key":"ref101","doi-asserted-by":"crossref","first-page":"1190","DOI":"10.2337\/db15-1356","article-title":"Shift to fatty substrate utilization in response to sodium-glucose cotransporter 2 inhibition in subjects without diabetes and patients with type 2 diabetes","volume":"65","year":"2016","journal-title":"Diabetes"},{"key":"ref221","doi-asserted-by":"crossref","first-page":"2324709617710040","DOI":"10.1177\/2324709617710040","article-title":"Prolonged ketosis in a patient with euglycemic diabetic ketoacidosis secondary to dapagliflozin","volume":"5","year":"2017","journal-title":"Journal of Investigative Medicine High Impact Case Reports"},{"key":"ref01","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1038\/nrendo.2011.243","article-title":"SGLT2 inhibition in diabetes mellitus: rationale and clinical prospects","volume":"8","year":"2012","journal-title":"Nature Reviews Endocrinology"},{"key":"ref421","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1093\/omcr\/omw061","article-title":"The DKA that wasn\u2019t: a case of euglycemic diabetic ketoacidosis due to empagliflozin","volume":"2016","year":"2016","journal-title":"Oxford Medical Case Reports"},{"key":"ref11","doi-asserted-by":"crossref","first-page":"2117","DOI":"10.1056\/NEJMoa1504720","article-title":"Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes","volume":"373","year":"2015","journal-title":"New England Journal of Medicine"},{"key":"ref471","first-page":"2654.e1","article-title":"SGLT2 inhibitor-associated diabetic ketoacidosis: clinical review and recommendations for prevention and diagnosis","volume":"38","year":"2016","journal-title":"Clinical Therapeutics"},{"key":"ref41","first-page":"2099","article-title":"Canagliflozin and cardiovascular and renal events in type 2 diabetes","volume":"377","year":"2017","journal-title":"New England Journal of Medicine"},{"key":"ref81","doi-asserted-by":"crossref","first-page":"508","DOI":"10.1111\/j.1464-5491.2011.03246.x","article-title":"Joint British Diabetes Societies guideline for the management of diabetic ketoacidosis","volume":"28","year":"2011","journal-title":"Diabetic Medicine"},{"key":"ref371","doi-asserted-by":"publisher","first-page":"201639","DOI":"10.2337\/dc16-0728","article-title":"FarjoPDKiddKMReeceJL case of euglycemic diabetic ketoacidosis following long - term empagliflozin therapy https org","journal-title":"Diabetes Care"},{"key":"ref351","article-title":"Ketosis and diabetic ketoacidosis in response to SGLT2 inhibitors: basic mechanisms and therapeutic perspectives","volume":"33","year":"2017","journal-title":"Diabetes\/Metabolism Research and Reviews"},{"key":"ref181","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1093\/omcr\/omw061","article-title":"The DKA that wasn\u2019t: a case of euglycemic diabetic ketoacidosis due to empagliflozin","volume":"2016","year":"2016","journal-title":"Oxford Medical Case Reports"},{"key":"ref261","doi-asserted-by":"crossref","first-page":"1687","DOI":"10.2337\/dc15-0843","article-title":"Euglycemic diabetic ketoacidosis: a potential complication of treatment with sodium-glucose cotransporter 2 inhibition","volume":"38","year":"2015","journal-title":"Diabetes Care"},{"key":"ref401","article-title":"Gonz\u00e1lez Sanchidri\u00e1nSG\u00f3mez ArroyoJRLabrador Diabetic ketoacidosis associated to canagliflozin in type diabetes https org","volume":"19","author":"Martino","journal-title":"Medicina"},{"key":"ref461","doi-asserted-by":"crossref","first-page":"2324709617710040","DOI":"10.1177\/2324709617710040","article-title":"Prolonged ketosis in a patient with euglycemic diabetic ketoacidosis secondary to dapagliflozin","volume":"5","year":"2017","journal-title":"Journal of Investigative Medicine High Impact Case Reports"},{"key":"ref21","doi-asserted-by":"crossref","first-page":"1687","DOI":"10.2337\/dc15-0843","article-title":"Euglycemic diabetic ketoacidosis: a potential complication of treatment with sodium-glucose cotransporter 2 inhibition","volume":"38","year":"2015","journal-title":"Diabetes Care"},{"key":"ref191","doi-asserted-by":"crossref","first-page":"187","DOI":"10.2169\/internalmedicine.56.7501","article-title":"Euglycemic diabetic ketoacidosis with persistent diuresis treated with canagliflozin","volume":"56","year":"2017","journal-title":"Internal Medicine"},{"key":"ref381","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1016\/j.jemermed.2016.07.082","article-title":"Euglycemic diabetic ketoacidosis with elevated acetone in a patient taking a sodium-glucose cotransporter-2 (SGLT2) inhibitor","volume":"52","year":"2017","journal-title":"Journal of Emergency Medicine"},{"key":"ref291","doi-asserted-by":"crossref","first-page":"2300","DOI":"10.1056\/NEJMc1701990","article-title":"Risk of diabetic ketoacidosis after initiation of an SGLT2 inhibitor","volume":"376","year":"2017","journal-title":"New England Journal of Medicine"},{"key":"ref231","first-page":"2654.e1","article-title":"SGLT2 inhibitor-associated diabetic ketoacidosis: clinical review and recommendations for prevention and diagnosis","volume":"38","year":"2016","journal-title":"Clinical Therapeutics"},{"key":"ref441","first-page":"1656182","article-title":"Severe ketoacidosis associated with canagliflozin (invokana): a safety concern","volume":"2016","year":"2016","journal-title":"Case Reports in Critical Care"},{"key":"ref301","doi-asserted-by":"crossref","first-page":"1638","DOI":"10.2337\/dc15-1380","article-title":"Euglycemic diabetic ketoacidosis: a predictable, detectable, and preventable safety concern with SGLT2 inhibitors","volume":"38","year":"2015","journal-title":"Diabetes Care"},{"key":"ref61","doi-asserted-by":"crossref","first-page":"1638","DOI":"10.2337\/dc15-1380","article-title":"Euglycemic diabetic ketoacidosis: a predictable, detectable, and preventable safety concern with SGLT2 inhibitors","volume":"38","year":"2015","journal-title":"Diabetes Care"},{"key":"ref151","doi-asserted-by":"crossref","first-page":"e3","DOI":"10.2337\/dc15-1797","article-title":"Euglycemic diabetic ketoacidosis in a patient with type 2 diabetes after treatment with empagliflozin","volume":"39","year":"2016","journal-title":"Diabetes Care"},{"key":"ref241","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1038\/nrendo.2011.243","article-title":"SGLT2 inhibition in diabetes mellitus: rationale and clinical prospects","volume":"8","year":"2012","journal-title":"Nature Reviews Endocrinology"},{"key":"ref411","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1111\/jdi.12330","article-title":"Case of ketoacidosis by a sodium-glucose cotransporter 2 inhibitor in a diabetic patient with a low-carbohydrate diet","volume":"6","year":"2015","journal-title":"Journal of Diabetes Investigation"},{"key":"ref281","first-page":"2099","article-title":"Canagliflozin and cardiovascular and renal events in type 2 diabetes","volume":"377","year":"2017","journal-title":"New England Journal of Medicine"},{"key":"ref211","doi-asserted-by":"crossref","first-page":"2324709617712736","DOI":"10.1177\/2324709617712736","article-title":"Euglycemic diabetic ketoacidosis with prolonged glucosuria associated with the sodium-glucose cotransporter-2 canagliflozin","volume":"5","year":"2017","journal-title":"Journal of Investigative Medicine High Impact Case Reports"},{"key":"ref251","doi-asserted-by":"crossref","first-page":"2117","DOI":"10.1056\/NEJMoa1504720","article-title":"Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes","volume":"373","year":"2015","journal-title":"New England Journal of Medicine"},{"key":"ref321","doi-asserted-by":"crossref","first-page":"508","DOI":"10.1111\/j.1464-5491.2011.03246.x","article-title":"Joint British Diabetes Societies guideline for the management of diabetic ketoacidosis","volume":"28","year":"2011","journal-title":"Diabetic Medicine"},{"key":"ref111","article-title":"Ketosis and diabetic ketoacidosis in response to SGLT2 inhibitors: basic mechanisms and therapeutic perspectives","volume":"33","year":"2017","journal-title":"Diabetes\/Metabolism Research and Reviews"},{"key":"ref121","doi-asserted-by":"crossref","first-page":"691","DOI":"10.1007\/s40262-015-0264-4","article-title":"Pharmacokinetics, pharmacodynamics and clinical use of SGLT2 inhibitors in patients with type 2 diabetes mellitus and chronic kidney disease","volume":"54","year":"2015","journal-title":"Clinical Pharmacokinetics"},{"key":"ref51","doi-asserted-by":"crossref","first-page":"2300","DOI":"10.1056\/NEJMc1701990","article-title":"Risk of diabetic ketoacidosis after initiation of an SGLT2 inhibitor","volume":"376","year":"2017","journal-title":"New England Journal of Medicine"},{"key":"ref141","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1016\/j.jemermed.2016.07.082","article-title":"Euglycemic diabetic ketoacidosis with elevated acetone in a patient taking a sodium-glucose cotransporter-2 (SGLT2) inhibitor","volume":"52","year":"2017","journal-title":"Journal of Emergency Medicine"},{"key":"ref171","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1111\/jdi.12330","article-title":"Case of ketoacidosis by a sodium-glucose cotransporter 2 inhibitor in a diabetic patient with a low-carbohydrate diet","volume":"6","year":"2015","journal-title":"Journal of Diabetes Investigation"},{"key":"ref331","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1002\/(SICI)1520-7560(199911\/12)15:6<412::AID-DMRR72>3.0.CO;2-8","article-title":"Ketone bodies: a review of physiology, pathophysiology and application of monitoring to diabetes","volume":"15","year":"1999","journal-title":"Diabetes\/Metabolism Research and Reviews"},{"key":"ref361","doi-asserted-by":"crossref","first-page":"691","DOI":"10.1007\/s40262-015-0264-4","article-title":"Pharmacokinetics, pharmacodynamics and clinical use of SGLT2 inhibitors in patients with type 2 diabetes mellitus and chronic kidney disease","volume":"54","year":"2015","journal-title":"Clinical Pharmacokinetics"},{"key":"ref271","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1016\/j.diabres.2017.04.017","article-title":"Effects of SGLT-2 inhibitors on diabetic ketoacidosis: a meta-analysis of randomised controlled trials","volume":"130","year":"2017","journal-title":"Diabetes Research and Clinical Practice"},{"key":"ref341","doi-asserted-by":"crossref","first-page":"1190","DOI":"10.2337\/db15-1356","article-title":"Shift to fatty substrate utilization in response to sodium-glucose cotransporter 2 inhibition in subjects without diabetes and patients with type 2 diabetes","volume":"65","year":"2016","journal-title":"Diabetes"},{"key":"ref451","doi-asserted-by":"crossref","first-page":"2324709617712736","DOI":"10.1177\/2324709617712736","article-title":"Euglycemic diabetic ketoacidosis with prolonged glucosuria associated with the sodium-glucose cotransporter-2 canagliflozin","volume":"5","year":"2017","journal-title":"Journal of Investigative Medicine High Impact Case Reports"},{"key":"ref91","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1002\/(SICI)1520-7560(199911\/12)15:6<412::AID-DMRR72>3.0.CO;2-8","article-title":"Ketone bodies: a review of physiology, pathophysiology and application of monitoring to diabetes","volume":"15","year":"1999","journal-title":"Diabetes\/Metabolism Research and Reviews"},{"key":"ref431","doi-asserted-by":"crossref","first-page":"187","DOI":"10.2169\/internalmedicine.56.7501","article-title":"Euglycemic diabetic ketoacidosis with persistent diuresis treated with canagliflozin","volume":"56","year":"2017","journal-title":"Internal Medicine"},{"key":"ref71","doi-asserted-by":"crossref","first-page":"753","DOI":"10.4158\/EP161292.PS","article-title":"American Association of Clinical Endocrinologists and American College of Endocrinology position statement on the association of SGLT-2 inhibitors and diabetic ketoacidosis","volume":"22","year":"2016","journal-title":"Endocrine Practices"}],"container-title":["Endocrinology, Diabetes & Metabolism Case Reports"],"original-title":[],"link":[{"URL":"https:\/\/edm.bioscientifica.com\/view\/journals\/edm\/2018\/1\/EDM17-0177.xml","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/edm.bioscientifica.com\/downloadpdf\/journals\/edm\/2018\/1\/EDM17-0177.xml","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,20]],"date-time":"2026-07-20T13:46:47Z","timestamp":1784555207000},"score":1,"resource":{"primary":{"URL":"http:\/\/journals.bioscientifica.com\/edm\/article\/3472"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,6,6]]},"references-count":48,"URL":"https:\/\/doi.org\/10.1530\/edm-17-0177","relation":{},"ISSN":["2052-0573"],"issn-type":[{"value":"2052-0573","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,6,6]]}}}